DAW1033D in Obstructive Sleep Apnea



Status:Active, not recruiting
Conditions:Insomnia Sleep Studies, Pulmonary, Pulmonary
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:21 - 65
Updated:3/27/2019
Start Date:December 13, 2017
End Date:November 1, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits

Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. In this protocol the investigators will test the effect of DAW1033D
administered before sleep on OSA phenotype traits and OSA severity during sleep.


Inclusion Criteria:

- AHI > 15

Exclusion Criteria:

- Any medical condition other than well controlled hypertension, diabetes,
hyperlipidemia

- Any medication known to influence breathing, sleep/arousal or muscle physiology.

- Claustrophobia.

- Inability to sleep supine.

- Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.

- Individuals with underlying cardiac disease, such as arrhythmias.

- Individuals taking psychiatric medications, or any of the studied medications for
medical care.

- History of seizures

- For women: Pregnancy.

- History of panic disorder / hyperventilation syndrome / Attention
deficit-hyperactivity disorder (ADHD) / autism
We found this trial at
1
site
Sleep Disorders Research Program Brigham and Women's Hospital
Boston, Massachusetts 02115
Phone: 617-732-6541
?
mi
from
Boston, MA
Click here to add this to my saved trials